NMRA vs. CRSP, KRYS, IBRX, IMVT, SWTX, DNLI, TWST, ACLX, NVAX, and APGE
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Arcellx (ACLX), Novavax (NVAX), and Apogee Therapeutics (APGE). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.
Neumora Therapeutics' return on equity of 0.00% beat CRISPR Therapeutics' return on equity.
In the previous week, CRISPR Therapeutics had 18 more articles in the media than Neumora Therapeutics. MarketBeat recorded 18 mentions for CRISPR Therapeutics and 0 mentions for Neumora Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.89 beat Neumora Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.
CRISPR Therapeutics has higher revenue and earnings than Neumora Therapeutics.
47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Neumora Therapeutics currently has a consensus target price of $22.57, indicating a potential upside of 126.85%. CRISPR Therapeutics has a consensus target price of $73.46, indicating a potential upside of 26.94%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than CRISPR Therapeutics.
CRISPR Therapeutics received 450 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 65.43% of users gave CRISPR Therapeutics an outperform vote.
Summary
CRISPR Therapeutics beats Neumora Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
